🇺🇸 FDA

Intelligence Platform

Patents

Browse 21 pharma-relevant US patents (A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 12359223

Systems and methods for modulating chromosomal rearrangements

Editas Medicine, Inc. · Granted Tue Jul 15 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 10 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12331328

CRISPR/Cas9-mediated exon-skipping approach for USH2A-associated usher syndrome

Editas Medicine, Inc. · Granted Tue Jun 17 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 12 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12325854

Crispr-CPF1-related methods, compositions and components for cancer immunotherapy

Editas Medicine, Inc. · Granted Tue Jun 10 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 05 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12201699

Compositions and methods for promoting homology directed repair

Editas Medicine, Inc. · Granted Tue Jan 21 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 16 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12031132

Systems and methods for the treatment of hemoglobinopathies

Editas Medicine, Inc. · Granted Tue Jul 09 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 04 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11963982

CRISPR/RNA-guided nuclease systems and methods

Editas Medicine, Inc. · Granted Tue Apr 23 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 18 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11952408

HPV-specific binding molecules

Editas Medicine, Inc. · Granted Tue Apr 09 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 04 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11911415

CRISPR/Cas-related methods and compositions for improving transplantation

Editas Medicine, Inc. · Granted Tue Feb 27 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 22 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11851690

Systems and methods for the treatment of hemoglobinopathies

Editas Medicine, Inc. · Granted Tue Dec 26 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 21 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11834649

CRISPR/CAS-related methods and compositions for treating herpes simplex virus

Editas Medicine, Inc. · Granted Tue Dec 05 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 30 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11806408

Methods and compositions for treating cone-rod retinal dystrophy

Editas Medicine, Inc. · Granted Tue Nov 07 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 02 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11667911

Use of exonucleases to improve CRISPR/CAS-mediated genome editing

Editas Medicine, Inc. · Granted Tue Jun 06 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 01 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11597924

Genome editing systems comprising repair-modulating enzyme molecules and methods of their

Editas Medicine, Inc. · Granted Tue Mar 07 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 02 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11566263

Compositions and methods for treating CEP290 associated disease

Editas Medicine, Inc. · Granted Tue Jan 31 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 26 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11390884

Optimized CRISPR/cas9 systems and methods for gene editing in stem cells

Editas Medicine, Inc. · Granted Tue Jul 19 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 14 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11390861

CRISPR/cas-related methods and compositions for treating herpes simplex virus

Editas Medicine, Inc. · Granted Tue Jul 19 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 14 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11242525

CRISPR/CAS-related methods and compositions for treating sickle cell disease

Editas Medicine, Inc. · Granted Tue Feb 08 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 03 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11141493

Compositions and methods for treating CEP290-associated disease

Editas Medicine, Inc. · Granted Tue Oct 12 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 07 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11028388

CRISPR/Cas-related methods and compositions for treating Usher syndrome and retinitis pigm

Editas Medicine, Inc. · Granted Tue Jun 08 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 03 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11001844

CRISPR/Cas-related methods and compositions for treating herpes simplex virus

Editas Medicine, Inc. · Granted Tue May 11 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 06 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 7788045

Systems and method for homeostatic blood states

MEDITASKS, LLC · Granted Tue Aug 31 2010 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 26 2030 00:00:00 GMT+0000 (Coordinated Universal Time)

granted